Search Results
Sep 15, 2025, 08:05 ET Avid Bioservices Welcomes Kenneth Bilenberg as new CEO
Sept. 15, 2025 /PRNewswire/ -- Avid Bioservices, Inc., a leading biologics contract development and manufacturing organization (CDMO), today announced the appointment of Kenneth Bilenberg as its new Chief Executive Officer (CEO). A seasoned industry executive with more than 20 years
More news about: Avid Bioservices
Sep 15, 2025, 08:00 ET Matica Bio Secures Commercial Manufacturing Deal with U.S. Biotech Company
/PRNewswire/ -- Matica Biotechnology, Inc. (Matica Bio), a leading contract development and manufacturing organization (CDMO) specializing in viral vector manufacturing for cell and gene therapies, today announced a strategic commercial manufacturing agreement with a clinical-stage
More news about: Matica Biotechnology, Inc.
Sep 15, 2025, 07:30 ET Abzena Enhances AbZelectPRO™ Cell Line Offering with New GS Knockout Platforms
Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, announced the expansion of its AbZelectPRO™
More news about: Abzena
Sep 15, 2025, 03:00 ET Mycenax et SPERA PHARMA concluent une alliance stratégique pour rationaliser les services de fabrication de substances médicamenteuses et de produits pharmaceutiques CAM
pharmaceutique japonais, SPERA PHARMA est considérée comme l'une des meilleures CDMO du pays. Ses partenaires internationaux lui font confiance pour son excellence technique et ses solutions CMC intégrées. Mycenax est une CDMO mondiale pour les produits biologiques auditée par des agences réglementaires
More news about: Mycenax Biotech Inc.
Sep 15, 2025, 03:00 ET Mycenax and SPERA PHARMA Forge Strategic Alliance to Streamline ADC Drug Substance and Drug Product Manufacturing Services
Sept. 15, 2025 /PRNewswire/ -- Mycenax Biotech Inc. (TWO:4726), a leading biologics CDMO based in Taiwan, today announced strategic alliance with SPERA PHARMA Inc., a Japan-based
More news about: Mycenax Biotech Inc.
Sep 15, 2025, 03:00 ET Mycenax und SPERA PHARMA schließen strategische Allianz zur Optimierung der Dienstleistungen im Bereich der Herstellung von ADC-Wirkstoffen und Arzneimitteln
15. September 2025 /PRNewswire/ -- Mycenax Biotech Inc. (TWO:4726), ein führendes CDMO-Unternehmen für Biologika mit Sitz in Taiwan, gab heute eine strategische Allianz mit SPERA PHARMA Inc. bekannt, einem
More news about: Mycenax Biotech Inc.
Sep 15, 2025, 03:00 ET Mycenax y SPERA PHARMA forjan una alianza estratégica
trayectoria farmacéutica de Japón, SPERA PHARMA es considerada una de las principales CDMO del país, y cuenta con la confianza de socios globales por su excelencia técnica y sus soluciones CMC integradas. Mycenax es una CDMO global de productos biológicos auditada por agencias reguladoras internacionales,
More news about: Mycenax Biotech Inc.